ArticleBMC cardiovascular disorders2026
Outcomes of anticoagulation initiation in critically ill patients with new-onset atrial fibrillation: a multicenter retrospective cohort study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNew-onset atrial fibrillation (NOAF) in intensive care units (ICU) carries a high risk of recurrence and atrial fibrillation (AF) related complications. However, evidence on the safety of anticoagulation (AC) in critically ill patients with NOAF is limited. This study aimed to evaluate the impact of AC initiation on clinical outcomes in this population.
methodsA multicentre, retrospective cohort study was conducted across four hospitals in Saudi Arabia from January 1, 2018, to February 28, 2024. Adult ICU patients (≥ 18 years) with documented NOAF were included and categorized into two groups: those who received anticoagulation (AC group) and those who did not (no AC group). The study outcomes were the incidence of bleeding or thrombotic events during a 1-year follow-up.
resultsA total of 179 patients were included, with 52.5% in the AC group and 47.4% in the no AC group. The overall bleeding incidence was 21.2% and did not differ between AC and non-AC groups (21.3% vs. 21.2%). Thrombotic events were infrequent (3.9%) with no significant between-group difference. Atrial fibrillation recurrence within one year occurred in 20.1% of patients and was similar across groups. After competing-risk analysis, therapeutic anticoagulation was not associated with increased bleeding risk (SHR 0.97; 95% CI 0.45–2.05). Prior bleeding history independently predicted bleeding. In time-varying Cox analysis, anticoagulation was not significantly associated with 30-day mortality (HR 0.81; 95% CI 0.38–1.70), whereas vasopressor use was associated with higher mortality risk.
conclusionsIn critically ill patients with NOAF, anticoagulation did not significantly alter the risk of bleeding or thrombotic events within 1 year of follow-up. These findings highlight the need for further prospective studies to guide anticoagulation decisions in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.